1,2-Diaminonaphthalen-3,6-disulfonsaeure | 88246-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2-Diaminonaphthalen-3,6-disulfonsaeure
• 英文别名: 3,4-diamino-2,7-naphthalene disulfonic acid；3,4-amino-2,7-napthalene disulfonic acid；DNDA；3,4-diamino-naphthalene-2,7-disulfonic acid；Naphthylendiamin-(1.2)-disulfonsaeure-(3.6)；3,4-Diamino-naphthalin-2,7-disulfonsaeure；3,4-Diaminonaphthalene-2,7-disulfonic acid
• CAS: 88246-88-2
• 化学式: C₁₀H₁₀N₂O₆S₂
• 分子量: 318.331
• InChiKey: VRJRYYZQHXJUEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  178
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,2-Diaminonaphthalen-3,6-disulfonsaeure 、 菲醌 在 sodium acetate 、 sodium hydrogensulfite 作用下， 生成 tribenzo[a,c,h]phenazine-10,13-disulfonic acid
  参考文献：
  名称：

  Fierz-David,H.E., Kuenstliche organische Farbstoffe,S.674

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基-2,7-萘二磺酸 在 偶氮苯 作用下， 生成 1,2-Diaminonaphthalen-3,6-disulfonsaeure
  参考文献：
  名称：

  Witt, Chemische Berichte, 1888, vol. 21, p. 3481

  摘要：

  DOI：

文献信息

• Method of treating melanoma using an inhibitor of an atypical protein kinase C
  申请人：UNIVERSITY OF SOUTH FLORIDA

  公开号：US10918650B2

  公开（公告）日：2021-02-16

  The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-ζ and/or PKC-ι. Non-limiting examples of an inhibitor of PKC-ζ and/or PKC-ι include ICA-1 and ACPD. The invention also provides PKC-ζ and/or PKC-ι as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-ζ and/or PKC-ι. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-ζ and/or PKC-ι based on the levels and/or activity of PKC-ζ and/or PKC-ι mRNA or protein in the melanoma cells from the subject are also provided.

  本发明涉及一种治疗黑色素瘤的方法，其方法是向有需要的受试者施用一种组合物，该组合物包含治疗有效量的PKC-ζ和/或PKC-ι抑制剂。PKC-ζ和/或PKC-ι抑制剂的非限制性实例包括ICA-1和ACPD。本发明还提供了PKC-ζ和/或PKC-ι作为生物标记物，用于鉴定受试者的黑色素瘤可能对使用PKC-ζ和/或PKC-ι抑制剂的疗法有反应或无反应。相应地，还提供了一种根据受试者黑色素瘤细胞中PKC-ζ和/或PKC-ι mRNA或蛋白质的水平和/或活性，确定受试者的黑色素瘤对使用PKC-ζ和/或PKC-ι抑制剂的黑色素瘤疗法有反应或无反应的方法。
• Wegmann,M., Diss.<Zuerich 1926>,S.72
  作者：Wegmann,M.

  DOI：——

  日期：——
• METHOD OF TREATING MELANOMA USING AN INHIBITOR OF AN ATYPICAL PROTEIN KINASE C
  申请人：Acevedo-Duncan Mildred Enid

  公开号：US20170348336A1

  公开（公告）日：2017-12-07

  The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-ζ and/or PKC-ι. Non-limiting examples of an inhibitor of PKC-ζ and/or PKC-ι include ICA- 1 and ACPD. The invention also provides PKC-ζ and/or PKC-ι as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-ζ and/or PKC-ι. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-ζ and/or PKC-ι based on the levels and/or activity of PKC-ζ and/or and/or PKC-ι mRNA or protein in the melanoma cells from the subject are also provided.